Pemfexy (Pemetrexed Injection for Intravenous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2020 Category: Drugs & Pharmacology Source Type: news

Alternative to Alimta Coming for Mesothelioma Patients
The U.S. Food and Drug Administration has granted final approval of Pemfexy, a new brand of the chemotherapy drug pemetrexed, to combat malignant mesothelioma and advanced stage non-small cell lung cancer. The approval will allow oncologists to offer an alternative to Alimta, which today is considered standard pemetrexed and manufactured by Eli Lilly and Company. The chemotherapy drug is designed to block DNA replication and cell division. However, Pemfexy will not be available until February 2022. The FDA approval is limited to pleural mesothelioma patients whose disease is unresectable. Pemfexy is produced by Eagle Pharm...
Source: Asbestos and Mesothelioma News - February 12, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pemfexy (Pemetrexed Injection for Intravenous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 12, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE) February 10, 2020 --Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the“Company”) today announced that it has received final approval from the U.S. Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 11, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Pemetrexed for Injection for Nonsquamous Non-Small Cell Lung Cancer
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - February 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going ...
Source: Asbestos and Mesothelioma News - January 27, 2020 Category: Environmental Health Authors: Matt Mauney Source Type: news

Latest Mesothelioma Clinical Trial Opens at Memorial Sloan Kettering
Memorial Sloan Kettering Cancer Center in New York City has opened its latest clinical trial for patients with pleural mesothelioma, studying the effectiveness of an immunotherapy and chemotherapy combination prior to aggressive surgery. The novel feasibility study will determine if the use of Opdivo (nivolumab) with Alimta (pemetrexed) and either cisplatin or carboplatin — without delaying scheduled surgery — can significantly extend patient survival time. The hope is to duplicate earlier effectiveness of that same combination with other cancers. “It has been tried with promising results,” Memorial...
Source: Asbestos and Mesothelioma News - November 27, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Miami Cancer Institute Begins Using Novel Treatment for Mesothelioma
The Miami Cancer Institute on Thursday will begin using the innovative Tumor Treating Fields device for patients with malignant pleural mesothelioma. It is the first new treatment approved for mesothelioma by the U.S. Food and Drug Administration in more than 15 years. “This is actually pretty exciting for us,” Dr. Rupesh Kotecha, the radiation oncologist who will oversee the treatment protocol in Miami, told The Mesothelioma Center at Asbestos.com. “It’s another tool in our armamentarium. It’s something we can offer patients that has shown a real benefit.” The noninvasive Tumor Treating...
Source: Asbestos and Mesothelioma News - November 6, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Pemetrexed + cisplatin in NSCLC not cost effective in Thailand
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2019 Category: Drugs & Pharmacology Source Type: news

Tumor Treating Fields Showing Early Success for Mesothelioma
Dr. Giovanni Ceresoli doesn’t think Tumor Treating Fields will work for every patient with mesothelioma cancer, but he knows it will work for some. They are in his clinic. As the principal investigator of the multicenter clinical trial that led to approval by the U.S. Food and Drug Administration in May, Ceresoli has played a major role in the development of this latest mesothelioma treatment. “It might be too early to say this is a major breakthrough — we need more data — but I hope it is. I know it’s something promising, very promising,” Cerosoli told The Mesothelioma Center at Asbest...
Source: Asbestos and Mesothelioma News - October 23, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Keytruda for Mesothelioma Flops in Phase III Clinical Trial
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - October 7, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Media News)
Source: Roche Media News - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT). (Source: Roche Investor Update)
Source: Roche Investor Update - September 27, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). (Source: Roche Media News)
Source: Roche Media News - September 12, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (Wild-Type or WT). (Source: Roche Investor Update)
Source: Roche Investor Update - September 12, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta
The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Co's lung cancer drug Alimta. (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Mesothelioma Study Explores New Treatment When Chemotherapy Fails
A clinical trial is exploring whether a novel immunotherapy/antiangiogenic combination can serve as an effective second-line treatment for pleural mesothelioma. Early indications of the four-center, phase II clinical trial are positive. The combination involves nivolumab (Opdivo) , a well-known immunotherapy drug, and ramucirumab (Cyramza), a therapy drug that blocks the formation of blood vessels needed for new tumor growth. The Food and Drug Administration approved both drugs for the treatment of other cancers, but this clinical trial is the first to test them in combination for mesothelioma. The single-arm trial began i...
Source: Asbestos and Mesothelioma News - August 26, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

What Is the Optimal Maintenance Therapy in Advanced NSCLC?
A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat  non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Once-Promising Drug Ofev Fails in Mesothelioma Clinical Trial
The search for a cure of mesothelioma hit another roadblock recently when a once-promising immunotherapy drug, combined with standard chemotherapy, failed to slow disease progression in a phase III study. The multicenter study covering 27 countries involved Ofev (nintedanib), a small-molecule enzyme inhibitor drug that had shown considerable potential in earlier studies. Lancet Respiratory Medicine published the trial results, signaling another setback for the highly anticipated use of certain immunotherapy drugs to treat mesothelioma. “Making significant improvements in systemic therapy for malignant pleural mesothe...
Source: Asbestos and Mesothelioma News - July 30, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Avastin Improves Quality of Life for Mesothelioma Patients
A research team from France has documented the health-related quality-of-life benefits of adding Avastin (bevacizumab) to chemotherapy for pleural mesothelioma patients, endorsing its addition to standard-of-care treatment. The recent quality-of-life analysis was a secondary endpoint of an earlier, multicenter clinical trial in France that showed an almost three-month median survival improvement when adding Avastin. The latest study demonstrated that adding Avastin to cisplatin and Alimta (pemetrexed) did not negatively impact quality of life — a problem with several other cancers because of the increased toxicity. &...
Source: Asbestos and Mesothelioma News - July 8, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Compound Could Make Chemotherapy More Effective
A research team from the Duke University Medical Center and the Massachusetts Institute of Technology has uncovered a new compound with potential to make chemotherapy more effective in treating various cancers. The small-molecule inhibitor drug — JH-RE-06 — showed an ability to better-sensitize tumors to Cisplatin, the popular chemotherapy drug most often used for mesothelioma cancer patients. When combined with Cisplatin, the drug also showed an ability to prevent those tumor cells from becoming treatment resistant, a common problem with this rare cancer caused by asbestos exposure. The research was done on l...
Source: Asbestos and Mesothelioma News - June 27, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Adding Bevacizumab Improves Overall Survival in NSCLC
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non - small cell lung cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 18, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Adding Bevacizumab Improves Overall Survival in NSCLC
TUESDAY, June 18, 2019 -- The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue of the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 18, 2019 Category: Pharmaceuticals Source Type: news

Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC
Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about  pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Suresh S. Ramalingam, MD Source Type: news

Addition of Maintenance Therapy Did Not Meet Primary Endpoint in Lung Cancer Trial
The addition of pemetrexed to bevacizumab maintenance therapy after induction therapy for chemo-naive patients with advanced lung cancer did not meet the primary endpoint in a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Chemo Regimen Boosts Gefitinib in EGFR-Mutant Lung Cancer, But at What Cost?
Researchers tested the addition of a pemetrexed-carboplatin chemotherapy regimen to gefitinib for patients with EGFR-mutant advanced non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 5, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

Adjuvant Pemetrexed Plus Cisplatin: A Safer Option for Non-Squamous NSCLC?
The study evaluated the efficacy and tolerability of adjuvant treatment with pemetrexed/cisplatin vs  vinorelbine/cisplatin in patients with non-squamous NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

FDA Approves First New Treatment for Mesothelioma in 15 Years
The U.S. Food & Drug Administration on Thursday approved Tumor Treating Fields, a therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth, for the first-line treatment of malignant pleural mesothelioma. It is the first treatment in more than 15 years that the FDA approves for mesothelioma. In 2004, the agency added the chemotherapy drug pemetrexed (Alimta) to standard-of-care treatment. The FDA approved Novocure’s NovoTTF-100L System under the agency’s Humanitarian Device Exemption. The approval comes eight months after Novocure, which manufactures and markets the dev...
Source: Asbestos and Mesothelioma News - May 24, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

FDA Approves First Mesothelioma Treatment in 15 Years FDA Approves First Mesothelioma Treatment in 15 Years
The NovoTTF-100L System is approved for use in combination with pemetrexed plus platinum-based chemotherapy in patients with malignant pleural mesothelioma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Survival Improves for Peritoneal Mesothelioma Patients in Finland
Survival time improved significantly for peritoneal mesothelioma patients in Finland who underwent a combination of surgery and chemotherapy, according to a recently released study. The five-year survival rate was 66 percent. The median survival was 62 months. According to a smaller, previous study in Finland, the median survival without treatment was just four months after diagnosis. “Despite these advances in treatment…the majority of patients with malignant peritoneal mesothelioma receive only palliative care of systemic chemotherapy, leaving many eligible patients without the benefit of this more invasive...
Source: Asbestos and Mesothelioma News - April 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Clinical trial finds therapy to be well-tolerated in patients with aggressive brain tumour
A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated in patients. The trial used a treatment combination of ADI-PEG20, pemetrexed and cisplatin, which showed encouraging efficacy in patients with recurrent high-grade gliomas (HGGs), a disease for which little progress has been made over the last few decades. (Source: World Pharma News)
Source: World Pharma News - March 29, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Targeting Blood-Clotting Pathway Improves Mesothelioma Treatment
A team of researchers at the Cancer and Vascular Biology Research Center in Haifa, Israel, and the Langone Medical Center in New York collaborated on research of a common blood-clotting pathway. Targeting this pathway may offer a unique avenue for improving existing mesothelioma treatments. Researchers said the standard first-line chemotherapy for malignant pleural mesothelioma — a combination of Alimta (pemetrexed) and cisplatin — offers little benefit to most mesothelioma patients. “This treatment regimen confers a median progression-free survival of 5.7 months,” according to the study published ...
Source: Asbestos and Mesothelioma News - March 5, 2019 Category: Environmental Health Authors: Walter Pacheco Source Type: news

New Immunotherapy Clinical Trial Targets Common Mesothelioma Protein
A biotechnology company specializing in innovative cancer therapeutics has opened a clinical trial examining an immunotherapy drug targeting a protein found in 90 percent of malignant mesothelioma tumors. It is the first clinical trial to specifically study a patient population characterized by this protein expression. The target is known as VISTA, a surface protein which inhibits the immune system from working properly and allows the mesothelioma to grow. The drug is CA-170, an orally available molecule and the only anti-VISTA drug being studied today in a cancer clinical trial. And the potential could be huge. “The...
Source: Asbestos and Mesothelioma News - February 19, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Dr. Mags Portman, HIV Prevention Pioneer, Dies from Mesothelioma at 44
Dr. Mags Portman, a British trailblazer in the fight to prevent and control HIV, died Wednesday after a two-year battle with mesothelioma. She was 44. Portman was lauded for triggering a significant reduction in HIV diagnoses throughout the United Kingdom by her work as a researcher, clinician and outspoken advocate. She earned international acclaim for her work as an HIV consultant at London’s Mortimer Market Centre, a progressive sexual health clinic that made pre-exposure prophylaxis (PrEP) a reality in the U.K. Portman played a key role in the 2014 study at The Royal London Hospital that proved the efficacy of t...
Source: Asbestos and Mesothelioma News - February 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Chemo-Carrying Gold Nanoparticles Tested on Mesothelioma
Italian researchers have found early success using gold nanoparticles as a chemotherapy-delivery vehicle for mesothelioma. They are hopeful their discovery will lead to an improvement in mesothelioma treatment in the future. The researchers tested their strategy on pleural mesothelioma cells in the lab. They first designed gold nanoparticles with a specific antibody targeted to the cells. Then they loaded the chemotherapy drug Alimta (pemetrexed) into the nanoparticles and observed its effect on the cancer cells. Delivering Alimta through the gold nanoparticles proved more effective than standard chemotherapy. But the me...
Source: Asbestos and Mesothelioma News - February 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Apatinib Case Study Uncovers Potential Mesothelioma Treatment
Doctors in China may have uncovered an effective second- or third-line treatment option for patients with malignant pleural mesothelioma. Dr. RongQin Meng, an oncologist at 363 Hospital in Cheng Du, said the investigational drug Apatinib (rivoceranib) could become part of a much-needed advance in mesothelioma treatment. After first- and second-line chemotherapy combinations had failed to slow tumor growth in a 58-year-old woman, Apatinib provided a five-month progression-free survival. “I was surprised at the result,” Meng told The Mesothelioma Center at Asbestos.com. “After taking the drug, the quality o...
Source: Asbestos and Mesothelioma News - January 31, 2019 Category: Environmental Health Authors: Daniel King Source Type: news

Vaccine and Chemotherapy Combo Shows Promise for Mesothelioma
Mesothelioma patients showed an impressive immune response to TroVax, a novel cancer vaccine, when it was combined with standard chemotherapy in a recent clinical trial. Researchers from Cardiff University in the United Kingdom conducted the study that was published by the journal OncoImmunology. TroVax is a laboratory engineered virus designed to target the human protein 5T4. A mutated form of 5T4 is found in almost all mesothelioma tumors, including the sarcomatoid subtype, the most difficult to treat. The phase II clinical trial produced a disease control rate of 87 percent, more than double the rate of a previous stud...
Source: Asbestos and Mesothelioma News - January 22, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response. Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level. Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent. PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - January 17, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Debate Continues on When Best to Use Mesothelioma Chemotherapy
This study is pretty reassuring that half the patients aren’t getting a more optimal or superior approach,” Simone said. “Both are good, accepted approaches. It’s more what the institution is comfortable with, and how the doctors are trained to do it.” European Trial May Be More Definitive The ongoing clinical trial is being done at centers in Belgium, France and the Netherlands. The European Organization for Research and Treatment of Cancer is sponsoring the study. The goal is 64 patients, half of whom will undergo pleurectomy and decortication surgery followed by three cycles of pemetrexed a...
Source: Asbestos and Mesothelioma News - January 3, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Alimta-Related Skin Reactions with and Without Oral Steroids
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote. The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - November 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

UK Study Matches Mesothelioma Treatments to Genetic Profile
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization. The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile. “We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step...
Source: Asbestos and Mesothelioma News - October 12, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Review Highlights Better Targets for Mesothelioma Therapy
A review on targeted therapies for malignant pleural mesothelioma (MPM) provides fresh insight into why this cancer is so difficult to treat and ideas for improving outcomes. “Despite more than two decades of intensive research on the possible treatments for MPM, the results have so far been disappointing,” the authors wrote. According to the in-depth review, published in Critical Reviews in Hematology/Oncology, the next steps toward more tailored mesothelioma treatment will come from learning more about the changes driving abnormal cell communication. Researchers will use this information to personalize treatm...
Source: Asbestos and Mesothelioma News - October 4, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news

Novel Mesothelioma Treatment Closer to FDA Approval
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - September 17, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

EC Approves Frontline Lung Cancer Combo EC Approves Frontline Lung Cancer Combo
The European Commission (EC) has approved the combination of pembrolizumab, pemetrexed, and platinum chemotherapy for the first-line treatment of metastatic non – small cell lung cancer.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Novocure touts combined TTF, chemotherapy mesothelioma study data
Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival. Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a median overall survival of 18.2 months, compared to 12.1 months in a historical control, the St. Helier, Jersey-based company said. Read the whole story on our sister site, Drug Delivery Business News The post No...
Source: Mass Device - September 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Drug-Device Combinations Oncology NovoCure Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - July 19, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2018 Category: Pharmaceuticals Source Type: news